4185 On Other Exchanges
Symbol
Exchange
4185 is not on other exchanges.

jsr corp (4185) Snapshot

Open
--
Previous Close
--
Day High
--
Day Low
--
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
--
Average Volume 10 Days
--
EPS TTM
--
Shares Outstanding
--
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for JSR CORP (4185)
\

Related News

No related news articles were found.

jsr corp (4185) Related Businessweek News

No Related Businessweek News Found

jsr corp (4185) Details

JSR Corporation provides petrochemical products, and fine chemicals and other products in Japan and internationally. The company operates through three segments: Elastomers Business, Plastics Business, and Fine Chemicals and Other Products Business. The Elastomers Business segment offers general purpose synthetic rubbers, including emulsion polymerization styrene-butadiene (SB), solution polymerization SB, styrene, polybutadiene, and isoprene rubbers; special-purpose synthetic rubbers, such as nitrile, butyl, ethylene propylene, and NV and NE polymer blend rubbers; and thermoplastic elastomers comprising syndiotactic 1,2-polybutadiene, hydrogenated polymers, SB thermoplastic elastomers, styrene-isoprene thermoplastic elastomers, TPE compound products, etc. It also provides emulsion products consisting of paper coating latex, SB latex, acrylic emulsions, asphalt pavement modifiers, etc.; and performance chemicals, including high-functional dispersants, organic/inorganic hybrid coating materials, battery materials, and thermal management materials. The Plastics Business segment offers styrenic resins, such as acrylonitrile-butadiene-styrene plastic and acrylonitrile-ethylene-propylene-styrene plastic products. The Fine Chemicals and Other Products Business segment provides semiconductor materials comprising lithography materials, chemical mechanical planarization materials, and packaging materials; display materials consisting of liquid crystal display and flat panel display materials; and optical materials, including precision and processing business materials. It also offers life sciences materials, such as in-vitro diagnostic and research reagents, and bioprocess materials; and lithium ion capacitors. The company was formerly known as Japan Synthetic Rubber Co., Ltd. JSR Corporation was founded in 1957 and is headquartered in Tokyo, Japan.

6,790 Employees
Last Reported Date: 06/16/17
Founded in 1957

jsr corp (4185) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

jsr corp
JSR Corporation Announces Consolidated Earnings Results for the Second Quarter Ended September 30, 2017; Provides Earnings Guidance for the Second Half Ending March 2018; Revises Capital Expenditures Guidance for the Year Ending March 2018

JSR Corporation announced consolidated earnings results for the second quarter and six months ended September 30, 2017. For the second quarter, the company's revenue was JPY 102,410 million. Operating profit was JPY 10,658 million. Profit attributable to owners of parent was JPY 8,521 million. For the second half ending March 2018, the company expects revenue of JPY 206,500 million, operating profit of JPY 19,600 million, profit attributable to owners of parent of JPY 13,500 million, and capital expenditures of JPY 26,100 million. For the year ending March 2018, the company expects capital expenditures of JPY 47,000 million against previous guidance of capital expenditures of JPY 31,800 million.

JSR Corporation Declares Dividend for the Second Quarter of Fiscal Year Ending March 31, 2018, Payable on November 30, 2017; Provides Year End Dividend Guidance for the Year-Ending March 31, 2018; Announces Consolidated Earnings Results for the First Six Months Ended September 30, 2017; Revises Consolidated Earnings Guidance for the Full Year Ending March 31, 2018

JSR Corporation declared dividend for the second quarter for the fiscal year ending March 31, 2018. For the second quarter-end, the company declared dividend of JPY 25.00 per share, compared with JPY 25.00 per share for the same period a year ago. Payable on November 30, 2017. For the year-end, the company expects to pay a dividend of JPY 25.00 per share, compared with JPY 25.00 per share for the same period a year ago. The company announced consolidated earnings results for the first six months ended September 30, 2017. For the period, the company reported revenue of JPY 203,538 million against JPY 182,229 million a year ago. Operating profit was JPY 23,365 million against JPY 14,953 million a year ago. Profit before tax was JPY 24,829 million against JPY 14,546 million a year ago. Profit was JPY 19,183 million against JPY 11,877 million a year ago. Profit attributable to owners of parent was JPY 17,970 million or JPY 80.52 per diluted share against JPY 11,696 million or JPY 51.88 per diluted share a year ago. The company revised consolidated earnings guidance for the full year ending March 31, 2018. For the year ending March 31, 2018, the company expects revenue of JPY 410,000 million, operating profit of JPY 43,000 million, profit before tax of JPY 44,500 million, profit of JPY 33,500 million and profit attributable to owners of parent of JPY 31,500 million or JPY 141.55 per basic share compared to previously expected revenue of JPY 405,000 million, operating profit of JPY 35,000 million, profit before tax of JPY 36,000 million, profit of JPY 28,000 million and profit attributable to owners of parent of JPY 26,500 million.

Vedanta Biosciences Licenses JSR Corporation's Key Intellectual Property

Vedanta Biosciences announced that it has exclusively sub-licensed key intellectual property from JSR Corporation to develop and commercialize microbiome-derived cancer immunotherapies based on live biotherapeutics. These live biotherapeutics have been shown to activate CD8+ T cells, a type of white blood cell that is the predominant effector in cancer immunotherapy. The sub-licensed intellectual property is based on the pioneering research of Dr. Kenya Honda, Professor, of Keio University School of Medicine and his collaborators in the University of Tokyo in Japan. An IND filing for the lead product candidate is planned in 2018.

 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

4185 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 4185.
View Industry Companies
 

Industry Analysis

4185

Industry Average

Valuation 4185 Industry Range
Price/Earnings 13.5x
Price/Sales 1.2x
Price/Book 1.3x
Price/Cash Flow 13.6x
TEV/Sales 0.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact JSR CORP, please visit www.jsr.co.jp. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.